news
As CRISPR-Cas9 starts to move into clinical trials, a new…
30 May 2017 | By Niamh Marriott (Drug Target Review)
As CRISPR-Cas9 starts to move into clinical trials, a new study has found that the gene-editing technology can introduce hundreds of unintended mutations into the genome.